Pre-surgery treatment for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests giving certain targeted drugs before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach helps reduce tumor size and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 70 years.
- Newly diagnosed breast cancer that has not spread to distant organs.
- Tumor tests positive for HER2 (a protein that helps breast cancer cells grow).
- Good overall health (able to carry out normal activities).
- No prior breast cancer treatment like chemotherapy or radiation.
- Normal heart function (checked by an echocardiogram).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.